PR Newswire BiotechOriginal article
2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
Phase 1IBI3003Positive
AI Analysis
Summary
Innovent Biologics announced updated Phase 1 clinical data for trispecific antibody IBI3003 (GPRC5D/BCMA/CD3) in patients with relapsed or refractory multiple myeloma at the 2026 IMS conference.
Clinical Trial Data
Phase
1
Outcome Details
Updated Phase 1 clinical data presented at IMS 2026
Importance:5/10
Sentiment:
0.30
trispecific antibodyoncologymultiple myelomaGPRC5DBCMACD3conference presentation
Read the original article
Published by PR Newswire Biotech on September 29, 2026 7:45 AM